Clinical trial · no report yet · Early phase 1

NCT03832569

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

NCT03832569 ↗
Active, not recruiting
Memorial Sloan Kettering Cancer Center
Focused

We haven't built an HCP commentary report on NCT03832569 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on NCT03832569 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
X threads	3

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Single-Arm Pilot Study of Adjuvant Pembrolizumab in Patients With MSI-H Tumors With Persistent Circulating Tumor DNA Following Surgery
Phase: Early phase 1
Status: Active, not recruiting
Conditions: Solid Tumors; Identified by NGS, PCR or IHC
Interventions: Pembrolizumab
Arms: Pembrolizumab · Experimental
Enrollment: 17
Primary outcomes: proportion of patients with ctDNA clearance
Sponsor: Memorial Sloan Kettering Cancer Center with Merck Sharp & Dohme LLC
Start: Feb 20, 2019
Primary completion: Feb 2027 (estimated)
Results posted: No
Registry record: NCT03832569 · updated Mar 5, 2026

Publications

linked from the registry

Cowzer D, Janjigian YY. Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer. 2022 May 15;128(10):1894-1899. doi: 10.1002/cncr.34140. Epub 2022 Feb 18. No abstract available. PubMed 35179774
Mendonca Gorgulho C, Krishnamurthy A, Lanzi A, Galon J, Housseau F, Kaneno R, Lotze MT. Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. J Immunother. 2021 Feb-Mar 01;44(2):49-62. doi: 10.1097/CJI.0000000000000357. PubMed 33416261